Symbols / KMDA $8.96 -0.22%
KMDA Chart
About
Kamada Ltd. manufactures and sells plasma-derived protein therapeutics. Its products include KAMRAB/KEDRAB indicated as prophylaxis of rabies; CYTOGAM for prophylaxis of Cytomegalovirus disease in kidney, lung, liver, pancreas, heart, and heart/lung transplants; VARIZIG for post exposure prophylaxis of varicella; WINRHO SDF for immune thrombocytopenic purpura and suppression of rhesus isoimmunization; HEPAGAM B for prevention of hepatitis B recurrence liver transplants and post-exposure prophylaxis; GLASSIA for intravenous AATD; KAMRHO (D) IM for prophylaxis of hemolytic disease of newborns; and Echis coloratus and Vipera palaestinae Antiserum to treat snake bite. The company also distributes biopharmaceutical products in Israel, including BRAMITOB to manage chronic pulmonary infection; FOSTER to treat asthma; TRIMBOW for chronic obstructive pulmonary disease; PROVOCHOLINE for the diagnosis of bronchial airway hyperactivity; AEROBIKA, an OPEP device; RUPAFIN and RUPAFIN ORAL SOLUTION for allergic rhinitis and Urticaria; SINTREDIUS for rheumatoid arthritis, systemic lupus erythematosus, and mild-moderate juvenile dermatomyositis; IVIG for various immunodeficiency-related conditions; VARITECT for chicken pox and zoster herpes; ZUTECTRA and HEPATECT CP for prevention of hepatitis B; MEGALOTECT CP for CMV virus; RUCONEST for angioedema attack; HEPARIN SODIUM INJECTION for thrombo-embolic disorders and prophylaxis of deep vein thrombosis and thromboembolic events; ALBUMIN and ALBUMIN for blood plasma; Factor VIII for hemophilia type A; and Factor IX for hemophilia type B. In addition, it distributes COAGADEX to treat hereditary factor X deficiency; IXIARO for Japanese encephalitis; VIVOTIF for salmonella typhi; PROCYSBI for nephropathic cystinosis; LAMZEDE for alpha-mannosidosis; RYPLAZIM for hypoplasminogenemia; ELIGARD for prostate cancer; and BEVACIZUMAB KAMADA for various cancers. The company was incorporated in 1990 and is headquartered in Rehovot, Israel.
Fundamentals
Scroll to Statements| Sector | Healthcare | Industry | Drug Manufacturers - Spe | Market Cap | 516.83M |
| Enterprise Value | 466.72M | Income | 20.44M | Sales | 174.79M |
| Book/sh | 4.51 | Cash/sh | 1.22 | Dividend Yield | — |
| Payout | 0.00% | Employees | 420 | IPO | — |
| P/E | 25.60 | Forward P/E | 18.67 | PEG | — |
| P/S | 2.96 | P/B | 1.99 | P/C | — |
| EV/EBITDA | 11.25 | EV/Sales | 2.67 | Quick Ratio | 2.24 |
| Current Ratio | 4.03 | Debt/Eq | 4.33 | LT Debt/Eq | — |
| EPS (ttm) | 0.35 | EPS next Y | 0.48 | EPS Growth | 28.60% |
| Revenue Growth | 12.60% | Earnings | 2026-03-11 | ROA | 4.76% |
| ROE | 7.86% | ROIC | — | Gross Margin | 43.75% |
| Oper. Margin | 16.63% | Profit Margin | 11.70% | Shs Outstand | 57.68M |
| Shs Float | 9.55M | Short Float | 0.53% | Short Ratio | 2.18 |
| Short Interest | — | 52W High | 9.35 | 52W Low | 5.54 |
| Beta | 0.30 | Avg Volume | 72.18K | Volume | 62.52K |
| Target Price | $13.00 | Recom | Strong_buy | Prev Close | $8.98 |
| Price | $8.96 | Change | -0.22% |
Valuation Models
Price estimates from analyst targets and simple models.
1. Analyst consensus
$13.00
Mean price target
2. Current target
$8.96
Latest analyst target
3. DCF / Fair value
$2.44
Simplified: (Free Cash Flow ÷ Shares) × 18 (P/FCF multiple). Not a …
Ratings
Current target
$8.96
Low
$11.00
High
$15.00
Mean
$13.00
Latest analyst rating changes
| Date | Action | Analyst | Rating Change | Price Target |
|---|---|---|---|---|
| 2025-12-09 | main | HC Wainwright & Co. | Buy → Buy | $13 |
| 2025-05-15 | reit | Benchmark | Buy → Buy | $15 |
| 2025-03-21 | init | Benchmark | — → Buy | $15 |
| 2025-03-06 | reit | HC Wainwright & Co. | Buy → Buy | $11 |
| 2025-01-10 | reit | HC Wainwright & Co. | Buy → Buy | $11 |
| 2024-11-14 | reit | HC Wainwright & Co. | Buy → Buy | $11 |
| 2024-08-15 | reit | HC Wainwright & Co. | Buy → Buy | $11 |
| 2024-07-03 | init | Stifel | — → Buy | $18 |
| 2024-05-09 | reit | HC Wainwright & Co. | Buy → Buy | $11 |
| 2024-03-07 | reit | HC Wainwright & Co. | Buy → Buy | $11 |
| 2023-11-14 | reit | HC Wainwright & Co. | Buy → Buy | $11 |
| 2023-08-17 | reit | HC Wainwright & Co. | Buy → Buy | $11 |
| 2023-05-25 | reit | HC Wainwright & Co. | Buy → Buy | $11 |
| 2023-03-16 | reit | HC Wainwright & Co. | — → Buy | $11 |
| 2018-02-02 | init | Chardan Capital | — → Buy | $7 |
| 2015-11-13 | main | Jefferies | — → Buy | $8 |
| 2013-06-25 | init | Jefferies | — → Buy | $15 |
| 2013-06-25 | init | Morgan Stanley | — → Equal-Weight | — |
| 2013-06-25 | init | Oppenheimer | — → Outperform | $14 |
- Kamada (NASDAQ:KMDA) Shares Cross Above Fifty Day Moving Average - Time to Sell? - MarketBeat ue, 10 Mar 2026 09
- Kamada to Announce Q4 Earnings on March 11 - Intellectia AI ue, 10 Mar 2026 18
- KMDA vs. ARGX: Which Stock Is the Better Value Option? - Yahoo Finance hu, 05 Mar 2026 16
- What's Next: Kamada's Earnings Preview - Benzinga ue, 10 Mar 2026 16
- Kamada Ltd. (KMDA) Stock Analysis: Unveiling a 51.69% Potential Upside in Healthcare Investments - DirectorsTalk Interviews Fri, 13 Feb 2026 08
- KAMADA Earnings Results: $KMDA Reports Quarterly Earnings - Quiver Quantitative Mon, 10 Nov 2025 08
- (KMDA) Price Dynamics and Execution-Aware Positioning - Stock Traders Daily Sun, 01 Mar 2026 13
- Ahead of Kamada (KMDA) Q4 Earnings: Get Ready With Wall Street Estimates for Key Metrics - Yahoo Finance Fri, 06 Mar 2026 14
- KMDA vs. ILMN: Which Stock Is the Better Value Option? - Nasdaq hu, 14 Aug 2025 07
- Kamada 2025/2026 Outlook: Evaluating Revenue Growth And Product Drivers (NASDAQ:KMDA) - Seeking Alpha hu, 08 Jan 2026 08
- KMDA or TECH: Which Is the Better Value Stock Right Now? - Yahoo Finance ue, 17 Feb 2026 08
- Why Is Kamada Stock Trading lower today - Kamada (NASDAQ:KMDA) - Benzinga Mon, 08 Dec 2025 08
- Ahead of Kamada (KMDA) Q4 Results: Prepare With Wall Street Projections for Essential Figures - Bitget hu, 05 Mar 2026 23
- Are Investors Undervaluing Kamada (KMDA) Right Now? - Yahoo Finance ue, 17 Feb 2026 08
- Kamada (KMDA) Soars 8.1%: Is Further Upside Left in the Stock? - Yahoo Finance ue, 27 Jan 2026 08
Insider Transactions
No recent insider transactions.
Financials
| Line Item | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| TaxEffectOfUnusualItems | -21.62K | 946.14 | 68.54K | -47.61K |
| TaxRateForCalcs | 0.23 | 0.02 | 0.23 | 0.23 |
| NormalizedEBITDA | 27.90M | 22.39M | 10.51M | 4.21M |
| TotalUnusualItems | -94.00K | 55.00K | 298.00K | -207.00K |
| TotalUnusualItemsExcludingGoodwill | -94.00K | 55.00K | 298.00K | -207.00K |
| NetIncomeFromContinuingOperationNetMinorityInterest | 14.46M | 8.28M | -2.32M | -2.23M |
| ReconciledDepreciation | 13.81M | 12.71M | 12.15M | 5.61M |
| ReconciledCostOfRevenue | 80.47M | 77.44M | 73.51M | 69.07M |
| EBITDA | 27.80M | 22.44M | 10.81M | 4.01M |
| EBIT | 13.99M | 9.73M | -1.34M | -1.60M |
| NetInterestIncome | 1.46M | -710.00K | -823.00K | 12.00K |
| InterestExpense | 660.00K | 1.30M | 914.00K | 283.00K |
| InterestIncome | 2.12M | 588.00K | 91.00K | 295.00K |
| NormalizedIncome | 14.53M | 8.23M | -2.55M | -2.07M |
| NetIncomeFromContinuingAndDiscontinuedOperation | 14.46M | 8.28M | -2.32M | -2.23M |
| TotalExpenses | 140.90M | 132.46M | 124.81M | 104.34M |
| TotalOperatingIncomeAsReported | 20.05M | 10.06M | 4.53M | -696.00K |
| DilutedAverageShares | 57.85M | 53.68M | 46.42M | 44.60M |
| BasicAverageShares | 57.85M | 48.83M | 46.42M | 44.60M |
| DilutedEPS | 0.25 | 0.15 | -0.05 | -0.05 |
| BasicEPS | 0.25 | 0.17 | -0.05 | -0.05 |
| DilutedNIAvailtoComStockholders | 14.46M | 8.28M | -2.32M | -2.23M |
| NetIncomeCommonStockholders | 14.46M | 8.28M | -2.32M | -2.23M |
| NetIncome | 14.46M | 8.28M | -2.32M | -2.23M |
| NetIncomeIncludingNoncontrollingInterests | 14.46M | 8.28M | -2.32M | -2.23M |
| NetIncomeContinuousOperations | 14.46M | 8.28M | -2.32M | -2.23M |
| TaxProvision | -1.13M | 145.00K | 62.00K | 345.00K |
| PretaxIncome | 13.33M | 8.43M | -2.26M | -1.89M |
| OtherIncomeExpense | -8.18M | -925.00K | -5.97M | -1.20M |
| OtherNonOperatingIncomeExpenses | -8.08M | -980.00K | -6.27M | -994.00K |
| GainOnSaleOfSecurity | -94.00K | 55.00K | 298.00K | -207.00K |
| NetNonOperatingInterestIncomeExpense | 1.46M | -710.00K | -823.00K | 12.00K |
| TotalOtherFinanceCost | 980.00K | 6.27M | 994.00K | |
| InterestExpenseNonOperating | 660.00K | 1.30M | 914.00K | 283.00K |
| InterestIncomeNonOperating | 2.12M | 588.00K | 91.00K | 295.00K |
| OperatingIncome | 20.05M | 10.06M | 4.53M | -696.00K |
| OperatingExpense | 49.92M | 45.43M | 42.17M | 31.02M |
| OtherOperatingExpenses | 601.00K | 919.00K | 912.00K | 753.00K |
| DepreciationAmortizationDepletionIncomeStatement | 3.30M | 3.12M | 3.03M | 1.36M |
| DepreciationAndAmortizationInIncomeStatement | 3.30M | 3.12M | 3.03M | 1.36M |
| ResearchAndDevelopment | 15.19M | 13.93M | 13.17M | 11.36M |
| SellingGeneralAndAdministration | 30.83M | 27.45M | 25.06M | 17.55M |
| SellingAndMarketingExpense | 10.43M | 9.20M | 9.18M | 3.86M |
| GeneralAndAdministrativeExpense | 20.41M | 18.25M | 15.88M | 13.69M |
| OtherGandA | 7.07M | 6.73M | 6.08M | 6.65M |
| SalariesAndWages | 13.34M | 11.53M | 9.80M | 7.04M |
| GrossProfit | 69.97M | 55.49M | 46.70M | 30.33M |
| CostOfRevenue | 90.99M | 87.03M | 82.64M | 73.31M |
| TotalRevenue | 160.95M | 142.52M | 129.34M | 103.64M |
| OperatingRevenue | 160.95M | 142.52M | 129.34M | 103.64M |
| Line Item | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| OrdinarySharesNumber | 57.51M | 57.48M | 44.83M | 44.80M |
| ShareIssued | 57.51M | 57.48M | 44.83M | 44.80M |
| NetDebt | 1.45M | |||
| TotalDebt | 11.06M | 8.82M | 20.60M | 24.35M |
| TangibleBookValue | 127.29M | 104.07M | 29.01M | 23.23M |
| InvestedCapital | 259.46M | 244.02M | 193.43M | 196.86M |
| WorkingCapital | 134.96M | 120.37M | 63.30M | 75.99M |
| NetTangibleAssets | 127.29M | 104.07M | 29.01M | 23.23M |
| CapitalLeaseObligations | 11.06M | 8.82M | 3.19M | 4.31M |
| CommonStockEquity | 259.46M | 244.02M | 176.02M | 176.82M |
| TotalCapitalization | 259.46M | 244.02M | 188.98M | 194.23M |
| TotalEquityGrossMinorityInterest | 259.46M | 244.02M | 176.02M | 176.82M |
| StockholdersEquity | 259.46M | 244.02M | 176.02M | 176.82M |
| OtherEquityInterest | 6.32M | 6.43M | 5.50M | 4.64M |
| GainsLossesNotAffectingRetainedEarnings | -3.08M | -3.08M | -3.23M | -3.58M |
| OtherEquityAdjustments | 51.00K | 140.00K | -88.00K | 54.00K |
| ForeignCurrencyTranslationAdjustments | -3.49M | -3.49M | -3.49M | -3.49M |
| MinimumPensionLiabilities | 364.00K | 275.00K | 348.00K | -149.00K |
| RetainedEarnings | -25.74M | -40.20M | -48.48M | -46.16M |
| AdditionalPaidInCapital | 266.93M | 265.85M | 210.50M | 210.20M |
| CapitalStock | 15.03M | 15.02M | 11.73M | 11.72M |
| CommonStock | 15.03M | 15.02M | 11.73M | 11.72M |
| TotalLiabilitiesNetMinorityInterest | 112.79M | 110.89M | 146.36M | 141.84M |
| TotalNonCurrentLiabilitiesNetMinorityInterest | 63.40M | 61.29M | 70.65M | 87.79M |
| OtherNonCurrentLiabilities | 53.46M | 53.23M | 54.84M | 65.92M |
| EmployeeBenefits | 509.00K | 621.00K | 672.00K | 1.28M |
| NonCurrentDeferredLiabilities | 0.00 | 15.00K | ||
| NonCurrentDeferredRevenue | 0.00 | 15.00K | ||
| LongTermDebtAndCapitalLeaseObligation | 9.43M | 7.44M | 15.14M | 20.57M |
| LongTermCapitalLeaseObligation | 9.43M | 7.44M | 2.18M | 3.16M |
| LongTermDebt | 12.96M | 17.41M | ||
| CurrentLiabilities | 49.39M | 49.59M | 75.70M | 54.06M |
| OtherCurrentLiabilities | 10.18M | 15.00M | 29.80M | 17.99M |
| CurrentDeferredLiabilities | 171.00K | 325.00K | 236.00K | 247.00K |
| CurrentDeferredRevenue | 171.00K | 325.00K | 236.00K | 247.00K |
| CurrentDebtAndCapitalLeaseObligation | 1.63M | 1.38M | 5.46M | 3.79M |
| CurrentCapitalLeaseObligation | 1.63M | 1.38M | 1.02M | 1.15M |
| CurrentDebt | 4.44M | 2.63M | ||
| OtherCurrentBorrowings | 4.44M | 2.63M | ||
| PensionandOtherPostRetirementBenefitPlansCurrent | 9.22M | 7.54M | 6.68M | 6.35M |
| PayablesAndAccruedExpenses | 28.19M | 25.35M | 33.53M | 25.69M |
| CurrentAccruedExpenses | 453.00K | 542.00K | 609.00K | 587.00K |
| Payables | 27.73M | 24.80M | 32.92M | 25.10M |
| AccountsPayable | 27.73M | 24.80M | 32.92M | 25.10M |
| TotalAssets | 372.25M | 354.91M | 322.38M | 318.67M |
| TotalNonCurrentAssets | 187.91M | 184.94M | 183.37M | 188.62M |
| OtherNonCurrentAssets | -1.00K | -1.00K | ||
| NonCurrentPrepaidAssets | 1.37M | 510.00K | 63.00K | 71.00K |
| NonCurrentDeferredAssets | 488.00K | 0.00 | ||
| NonCurrentDeferredTaxesAssets | 488.00K | 0.00 | ||
| NonCurrentAccountsReceivable | 8.02M | 8.49M | 7.58M | 5.56M |
| GoodwillAndOtherIntangibleAssets | 132.17M | 139.96M | 147.01M | 153.59M |
| OtherIntangibleAssets | 101.86M | 109.64M | 116.70M | 123.28M |
| Goodwill | 30.31M | 30.31M | 30.31M | 30.31M |
| NetPPE | 45.86M | 35.98M | 28.73M | 29.40M |
| AccumulatedDepreciation | -64.86M | -60.41M | -56.21M | -52.26M |
| GrossPPE | 110.73M | 96.39M | 84.94M | 81.66M |
| Leases | 9.04M | 3.09M | 1.57M | 1.18M |
| OtherProperties | 15.00K | 1.00K | 7.00K | 15.00K |
| MachineryFurnitureEquipment | 56.11M | 50.90M | 46.54M | 43.75M |
| BuildingsAndImprovements | 8.23M | 6.36M | 1.73M | 2.17M |
| LandAndImprovements | 37.32M | 36.04M | 35.09M | 34.54M |
| Properties | 0.00 | 0.00 | 0.00 | 0.00 |
| CurrentAssets | 184.35M | 169.96M | 139.00M | 130.04M |
| HedgingAssetsCurrent | 49.00K | 149.00K | 0.00 | 73.00K |
| PrepaidAssets | 3.85M | 4.41M | 3.88M | 3.99M |
| Inventory | 78.82M | 88.48M | 72.52M | 71.83M |
| OtherInventories | 9.75M | 11.02M | 8.49M | 10.66M |
| FinishedGoods | 29.37M | 42.53M | 30.43M | 36.27M |
| WorkInProcess | 9.16M | 6.65M | 12.28M | 8.08M |
| RawMaterials | 30.54M | 28.28M | 21.33M | 16.82M |
| Receivables | 23.20M | 21.29M | 28.36M | 35.56M |
| OtherReceivables | 1.81M | 1.56M | 1.23M | 733.00K |
| AccountsReceivable | 21.39M | 19.73M | 27.13M | 34.83M |
| AllowanceForDoubtfulAccountsReceivable | 0.00 | 0.00 | 0.00 | |
| GrossAccountsReceivable | 21.39M | 19.73M | 27.13M | 34.83M |
| CashCashEquivalentsAndShortTermInvestments | 78.44M | 55.64M | 34.26M | 18.59M |
| OtherShortTermInvestments | 0.00 | |||
| CashAndCashEquivalents | 78.44M | 55.64M | 34.26M | 18.59M |
| CashEquivalents | 55.30M | 15.01M | 2.85M | 3.22M |
| CashFinancial | 23.13M | 40.63M | 31.41M | 15.37M |
| Line Item | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| FreeCashFlow | 36.85M | -1.53M | 24.80M | -12.55M |
| RepaymentOfDebt | -1.25M | -18.26M | -3.73M | -1.43M |
| IssuanceOfDebt | 0.00 | 0.00 | 20.00M | |
| IssuanceOfCapitalStock | 0.00 | 58.23M | 0.00 | 0.00 |
| CapitalExpenditure | -10.74M | -5.85M | -3.78M | -3.73M |
| EndCashPosition | 78.44M | 55.64M | 34.26M | 18.59M |
| BeginningCashPosition | 55.64M | 34.26M | 18.59M | 70.20M |
| EffectOfExchangeRateChanges | -150.00K | 233.00K | 212.00K | -334.00K |
| ChangesInCash | 22.94M | 21.15M | 15.46M | -51.28M |
| FinancingCashFlow | -13.91M | 22.68M | -9.34M | 18.59M |
| CashFlowFromContinuingFinancingActivities | -13.91M | 22.68M | -9.34M | 18.59M |
| NetOtherFinancingCharges | -12.67M | -17.30M | -5.63M | |
| ProceedsFromStockOptionExercised | 7.00K | 4.00K | 9.00K | 19.00K |
| NetCommonStockIssuance | 0.00 | 58.23M | 0.00 | 0.00 |
| CommonStockIssuance | 0.00 | 58.23M | 0.00 | 0.00 |
| NetIssuancePaymentsOfDebt | -1.25M | -18.26M | -3.73M | 18.57M |
| NetLongTermDebtIssuance | -1.25M | -18.26M | -3.73M | 18.57M |
| LongTermDebtPayments | -1.25M | -18.26M | -3.73M | -1.43M |
| LongTermDebtIssuance | 0.00 | 0.00 | 20.00M | |
| InvestingCashFlow | -10.74M | -5.84M | -3.78M | -61.05M |
| CashFlowFromContinuingInvestingActivities | -10.74M | -5.84M | -3.78M | -61.05M |
| NetInvestmentPurchaseAndSale | 0.00 | 0.00 | 39.08M | |
| SaleOfInvestment | 39.08M | |||
| NetBusinessPurchaseAndSale | 0.00 | -96.40M | ||
| PurchaseOfBusiness | 0.00 | -96.40M | ||
| NetPPEPurchaseAndSale | -10.74M | -5.84M | -3.78M | -3.73M |
| SaleOfPPE | 1.00K | 7.00K | 0.00 | 0.00 |
| PurchaseOfPPE | -10.74M | -5.85M | -3.78M | -3.73M |
| OperatingCashFlow | 47.59M | 4.32M | 28.59M | -8.82M |
| CashFlowFromContinuingOperatingActivities | 47.59M | 4.32M | 28.59M | -8.82M |
| TaxesRefundPaid | -139.00K | -217.00K | -36.00K | -42.00K |
| InterestReceivedCFO | 2.12M | 0.00 | 97.00K | 375.00K |
| InterestPaidCFO | -594.00K | -1.23M | -853.00K | -228.00K |
| ChangeInWorkingCapital | 11.41M | -18.20M | 11.65M | -14.41M |
| ChangeInOtherWorkingCapital | 23.00K | 113.00K | -20.00K | -5.07M |
| ChangeInPayablesAndAccruedExpense | 2.64M | -8.12M | 7.34M | 7.53M |
| ChangeInPayable | 2.64M | -8.12M | 7.34M | 7.53M |
| ChangeInAccountPayable | 1.23M | -8.88M | 7.05M | 7.92M |
| ChangeInInventory | 9.66M | -19.69M | -1.36M | -2.37M |
| ChangeInReceivables | -908.00K | 9.50M | 5.68M | -14.49M |
| ChangesInAccountReceivables | -1.98M | 7.83M | 7.60M | -12.86M |
| OtherNonCashItems | 6.72M | 1.64M | 6.79M | 1.19M |
| StockBasedCompensation | 874.00K | 1.31M | 1.15M | 529.00K |
| DeferredTax | -1.13M | 145.00K | 62.00K | 345.00K |
| DeferredIncomeTax | -1.13M | 145.00K | 62.00K | 345.00K |
| DepreciationAmortizationDepletion | 13.81M | 12.71M | 12.15M | 5.61M |
| DepreciationAndAmortization | 13.81M | 12.71M | 12.15M | 5.61M |
| Depreciation | 12.71M | 12.15M | 5.61M | |
| OperatingGainsLosses | 63.00K | -130.00K | -111.00K | 45.00K |
| PensionAndEmployeeBenefitExpense | 52.00K | -125.00K | -111.00K | 45.00K |
| GainLossOnSaleOfPPE | 11.00K | -5.00K | 0.00 | 0.00 |
| NetIncomeFromContinuingOperations | 14.46M | 8.28M | -2.32M | -2.23M |
SEC Filings
No SEC filings found for this symbol (may be non-US or ticker not in SEC index).
Public Trades for KMDA
| Date | User | Broker | Pattern | Type | Position Size | Entry Price | Trade P&L | Status |
|---|